비스테로이드성 항염증제(NSAIDs) 시장 - 세계 시장 예측(2026-2032년)

The Non-steroidal Anti-inflammatory Drugs Market is projected to grow by USD 38.81 billion at a CAGR of 6.71% by 2032.

Non-steroidal anti-inflammatory drugs (NSAIDs) remain among the most widely used therapeutic options for pain, inflammation, and fever management across prescription and over-the-counter healthcare settings. The category includes nonselective cyclooxygenase inhibitors and COX-2 selective agents used in conditions such as osteoarthritis, rheumatoid arthritis, musculoskeletal pain, dysmenorrhea, headache, dental pain, postoperative pain, and acute inflammatory disorders. Demand is shaped by aging populations, rising chronic pain prevalence, expanding self-medication behavior, and continued clinical reliance on NSAIDs as opioid-sparing analgesics.

The NSAID landscape is also defined by well-documented safety considerations, including gastrointestinal bleeding, renal impairment, cardiovascular risk, blood pressure elevation, hypersensitivity reactions, and drug-drug interactions, particularly in older adults and patients with comorbidities. Regulatory agencies and clinical guidelines consistently emphasize risk stratification, lowest effective dose, shortest appropriate duration, gastroprotection for high-risk patients, and careful selection based on individual cardiovascular, gastrointestinal, renal, hepatic, and pregnancy-related profiles. As healthcare systems pursue safer pain management pathways, NSAID strategies are increasingly focused on formulation innovation, real-world evidence, pharmacovigilance, digital decision support, and improved patient education.

Transformative Shifts in the NSAID Landscape

The NSAID sector is undergoing structural change as healthcare providers balance broad accessibility with heightened safety expectations. A major shift is the continued movement from generalized pain treatment toward personalized analgesic selection, where clinicians evaluate gastrointestinal risk, cardiovascular history, kidney function, age, concomitant anticoagulants, antiplatelets, corticosteroids, selective serotonin reuptake inhibitors, antihypertensive therapies, and pregnancy status before recommending an NSAID. This approach reflects stronger integration of evidence-based prescribing and medication safety protocols in primary care, rheumatology, orthopedics, dentistry, sports medicine, and perioperative care.

Another transformative shift is the rising preference for topical NSAID formulations in localized musculoskeletal conditions, particularly among older adults and patients at elevated systemic adverse-event risk. Clinical guidance in several jurisdictions supports topical options for specific osteoarthritis and soft-tissue pain applications due to lower systemic exposure compared with oral formulations. At the same time, opioid stewardship programs have strengthened the role of NSAIDs in multimodal pain management, especially when combined with acetaminophen, physical therapy, local interventions, or nonpharmacological approaches. Regulatory scrutiny of labeling, contraindications, pediatric use, pregnancy warnings, cardiovascular risk communication, and over-the-counter dosing instructions continues to influence product positioning and patient counseling. Supply chain resilience, active pharmaceutical ingredient quality, and pharmacovigilance systems are also becoming critical competitive differentiators.

Cumulative Impact of Artificial Intelligence on NSAIDs

Artificial intelligence is increasingly influencing the NSAID value chain through drug safety analytics, clinical decision support, patient engagement, and research acceleration. In pharmacovigilance, AI-enabled natural language processing and signal detection can help analyze adverse-event reports, electronic health records, claims data, scientific literature, and consumer safety narratives to identify patterns related to gastrointestinal bleeding, renal injury, cardiovascular events, hypersensitivity reactions, medication overuse, and drug-drug interactions. These capabilities support faster triage of safety signals and more targeted risk-management activities while requiring human oversight, validated datasets, and transparent governance.

In clinical practice, AI-based decision support can assist prescribers and pharmacists by flagging patients at elevated NSAID risk, identifying contraindicated combinations, recommending renal function monitoring, or prompting gastroprotective strategies where clinically appropriate. AI can also support patient-facing tools that improve adherence to dosing instructions and reduce inappropriate long-duration use of over-the-counter NSAIDs. In research and development, machine learning is being used to screen anti-inflammatory mechanisms, model COX selectivity, assess toxicity signals earlier, optimize formulation characteristics, and support real-world evidence studies. However, AI adoption must address data bias, privacy regulations, explainability, cybersecurity, and clinical validation to ensure that algorithmic recommendations improve outcomes without increasing medication-related harm.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

In Asia-Pacific, NSAID use is supported by large patient populations, high incidence of musculoskeletal disorders, rapid urbanization, expanding pharmacy access, and growing healthcare utilization in countries such as China, India, Japan, South Korea, and Australia. The region combines mature regulatory environments with rapidly developing healthcare systems, creating varied patterns of prescription control, over-the-counter availability, and patient self-medication. In North America, NSAID demand is shaped by chronic pain management, sports injuries, arthritis burden, opioid-sparing clinical protocols, and strong pharmacovigilance expectations. The United States and Canada place considerable emphasis on labeling, cardiovascular and gastrointestinal warnings, medication therapy management, and evidence-based prescribing.

Latin America presents a diverse environment where Brazil and Mexico are key drivers of retail pharmacy access and self-care behavior, while public health systems continue to address affordability, quality assurance, and rational medicine use. Europe is characterized by mature regulatory oversight, strong primary care systems, pharmacovigilance infrastructure, and active clinical guidance on NSAID risk mitigation, particularly for older adults and patients with cardiovascular, gastrointestinal, or renal vulnerabilities. The Middle East shows increasing use of NSAIDs through expanding hospital networks, private healthcare investment, insurance coverage, and rising chronic disease diagnosis, with Gulf countries placing greater emphasis on regulated pharmacy distribution and digital health infrastructure. Across Africa, access patterns vary widely, with NSAID use influenced by affordability, essential medicines policies, informal medicine channels, urban-rural healthcare gaps, and the need for stronger patient education on safe dosing, contraindications, and avoidance of harmful medicine combinations.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are experiencing rising NSAID utilization due to expanding urban healthcare access, a growing middle class, high retail pharmacy engagement, and increased recognition of musculoskeletal and inflammatory conditions. Variability in regulatory enforcement and self-medication practices makes pharmacist counseling and public education especially important across the group. The GCC shows strong momentum in regulated healthcare delivery, e-prescription systems, insurance-backed access, and hospital-based pain management protocols, while the high prevalence of metabolic, renal, and cardiovascular risk factors increases the importance of NSAID risk assessment.

Within the European Union, harmonized regulatory frameworks, robust pharmacovigilance, and coordinated medicine safety communications shape NSAID prescribing and labeling practices. EU healthcare systems place growing emphasis on appropriate use in elderly populations, renal monitoring, gastrointestinal protection, and minimization of preventable adverse drug events. BRICS countries combine large treatment populations with expanding domestic pharmaceutical capacity, increasing attention to quality standards, local manufacturing, and access to affordable pain therapies. G7 markets are defined by advanced clinical governance, strong evidence generation, digital health adoption, and mature OTC frameworks, making safety communication and real-world outcomes central priorities. NATO member countries overlap substantially with developed healthcare systems in North America and Europe, where NSAID use is influenced by military readiness, injury management, rehabilitation needs, perioperative care, and standardized clinical pathways for acute and chronic pain.

Key Country Insights Across Major NSAID Markets

The United States is shaped by extensive OTC NSAID availability, opioid-sparing pain management, and strong attention to cardiovascular, gastrointestinal, renal, and pregnancy-related warnings. Canada emphasizes pharmacist involvement, evidence-based self-care, and careful NSAID use among older adults and patients with chronic disease. Mexico demonstrates significant retail pharmacy engagement and demand for affordable analgesics, making rational use and consumer education central to safe access. Brazil combines high demand for pain and inflammation treatment with an evolving regulatory focus on medicine quality, pharmacy practices, and pharmacovigilance.

The United Kingdom, Germany, France, Italy, and Spain operate within mature European healthcare systems where clinical guidelines, prescription controls, and pharmacovigilance systems support risk-based NSAID use. Germany and France have strong physician-led prescribing cultures and established reimbursement frameworks, while the United Kingdom emphasizes primary care guidance and national medicine safety communications. Italy and Spain show substantial use in musculoskeletal pain and rheumatologic conditions, with increasing attention to older adult safety, gastroprotection, and renal risk. Russia maintains notable demand for analgesics and anti-inflammatory therapies, with access shaped by domestic pharmaceutical capacity, pharmacy distribution, and regulatory oversight.

China has broad NSAID utilization driven by a large patient base, expanding healthcare coverage, and growing treatment of arthritis and acute pain conditions. India reflects strong demand for affordable pain relief, but safe use depends heavily on physician guidance, pharmacist intervention, and control of inappropriate self-medication. Japan's aging population and high standards for medicine safety support careful NSAID selection, including attention to gastrointestinal protection and renal function. Australia has a well-established OTC and prescription environment, with public health guidance stressing safe dosing, contraindication awareness, and avoidance of use in high-risk patients without professional advice. South Korea combines advanced healthcare infrastructure, high digital adoption, and strong clinical management of chronic pain and inflammatory disorders, supporting continued refinement of NSAID stewardship.

Actionable Recommendations for NSAID Industry Leaders

Industry leaders should prioritize safety-led differentiation by investing in clearer labeling, patient education, pharmacist training, and risk-screening tools that support appropriate NSAID use. Product strategies should align with clinical demand for topical formulations, gastroprotective co-therapy considerations, controlled-release technologies where appropriate, and formulations that improve convenience while maintaining safety standards. Organizations should also strengthen pharmacovigilance systems by integrating real-world evidence, adverse-event monitoring, and proactive safety signal assessment across prescription and OTC channels.

Commercial and medical teams should collaborate with healthcare professionals to support evidence-based NSAID stewardship, especially for high-risk populations such as older adults, patients with cardiovascular disease, chronic kidney disease, peptic ulcer history, hypertension, pregnancy considerations, and those using anticoagulants or antiplatelet agents. Digital tools should be developed responsibly to guide dose selection, duration reminders, contraindication checks, renal monitoring prompts, and patient counseling. Supply chain strategies should emphasize active ingredient quality, regulatory compliance, manufacturing redundancy, and transparent sourcing. In emerging markets, leaders should focus on affordability, counterfeit prevention, rational medicine use, and pharmacy-based education to improve access without compromising safety.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available and verifiable sources, including regulatory guidance, clinical practice recommendations, pharmacovigilance communications, peer-reviewed medical literature, public health publications, and medicine safety resources. The methodology emphasizes triangulation across multiple evidence categories to ensure that statements reflect established clinical and regulatory knowledge rather than speculative market assumptions.

Research inputs are assessed for relevance to NSAID pharmacology, therapeutic use, safety risks, regional access patterns, regulatory controls, OTC availability, prescribing behavior, and emerging digital health applications. Regional, group, and country insights are synthesized qualitatively to identify adoption drivers, safety priorities, and healthcare system dynamics. The analysis avoids market sizing, share estimation, and forecasting, focusing instead on data-backed industry context, clinical relevance, regulatory direction, and actionable strategic implications for stakeholders across the NSAID ecosystem.

Conclusion: Responsible Access and Safety-Led Innovation Define the Future of NSAIDs

Non-steroidal anti-inflammatory drugs continue to play a central role in global pain and inflammation management, supported by broad clinical utility, extensive OTC access, and increasing relevance in opioid-sparing treatment strategies. At the same time, the category requires disciplined safety management due to well-established gastrointestinal, renal, cardiovascular, pregnancy-related, and interaction risks. The most competitive and clinically responsible approaches will be those that combine accessibility with risk-based guidance, formulation innovation, pharmacovigilance, and transparent patient communication.

Regional and country-level differences in healthcare infrastructure, regulatory enforcement, pharmacy practice, and self-medication behavior will continue to shape NSAID utilization. Artificial intelligence, real-world evidence, and digital decision support can enhance safety monitoring and personalized use when implemented with strong governance and clinical validation. Industry leaders that prioritize responsible access, evidence-based education, and safety-centered innovation will be best positioned to meet evolving healthcare expectations in the NSAID landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Acetic Acid Derivatives
  • 7.2.1. Diclofenac
  • 7.2.2. Ketorolac
• 7.3. Fenamates
  • 7.3.1. Flufenamic Acid
  • 7.3.2. Mefenamic Acid
• 7.4. Oxicams
  • 7.4.1. Piroxicam
  • 7.4.2. Tenoxicam
• 7.5. Propionic Acid Derivatives
  • 7.5.1. Flurbiprofen
  • 7.5.2. Ibuprofen
  • 7.5.3. Ketoprofen
  • 7.5.4. Naproxen
• 7.6. Salicylates
  • 7.6.1. Aspirin
  • 7.6.2. Diflunisal
• 7.7. Selective COX-2 Inhibitors (Coxibs)
  • 7.7.1. Celecoxib
  • 7.7.2. Etoricoxib

8. Non-steroidal Anti-inflammatory Drugs Market, by Formulation

• 8.1. Introduction
• 8.2. Capsules
• 8.3. Creams/Gels
• 8.4. Powders
• 8.5. Tablets

9. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Oral
• 9.3. Parenteral
• 9.4. Topical

10. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status

• 10.1. Introduction
• 10.2. Over-The-Counter
• 10.3. Prescription Only

11. Non-steroidal Anti-inflammatory Drugs Market, by Release Type

• 11.1. Introduction
• 11.2. Immediate-Release
• 11.3. Modified-Release
  • 11.3.1. Controlled-Release
  • 11.3.2. Delayed-Release/Enteric-Coated
  • 11.3.3. Extended-Release

12. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

• 12.1. Introduction
• 12.2. Adults
• 12.3. Geriatric
• 12.4. Pediatric
• 12.5. Introduction
• 12.6. Adults
• 12.7. Geriatric
• 12.8. Pediatric

13. Non-steroidal Anti-inflammatory Drugs Market, by Indication

• 13.1. Introduction
• 13.2. Acute Pain
  • 13.2.1. Dental Pain
  • 13.2.2. Musculoskeletal Injury (Sprain/Strain)
  • 13.2.3. Postoperative Pain
• 13.3. Ankylosing Spondylitis
• 13.4. Dysmenorrhea
• 13.5. Fever/Pyrexia
• 13.6. Migraine & Headache
• 13.7. Ophthalmic Pain & Inflammation
• 13.8. Osteoarthritis
• 13.9. Rheumatoid Arthritis

14. Non-steroidal Anti-inflammatory Drugs Market, by End User

• 14.1. Introduction
• 14.2. Ambulatory Surgical Centers
• 14.3. Homecare
• 14.4. Hospitals
• 14.5. Specialty Clinics

15. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

• 15.1. Introduction
• 15.2. Hospital Pharmacies
• 15.3. Online Pharmacies
• 15.4. Retail Pharmacies

16. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

• 16.1. Introduction
• 16.2. Adults
• 16.3. Geriatric
• 16.4. Pediatric
• 16.5. Introduction
• 16.6. Adults
• 16.7. Geriatric
• 16.8. Pediatric

17. Non-steroidal Anti-inflammatory Drugs Market, by Region

• 17.1. Europe
• 17.2. North America
• 17.3. Asia-Pacific
• 17.4. Latin America
• 17.5. Africa
• 17.6. Middle East

18. Non-steroidal Anti-inflammatory Drugs Market, by Group

• 18.1. NATO
• 18.2. G7
• 18.3. European Union
• 18.4. BRICS
• 18.5. ASEAN
• 18.6. GCC

19. Non-steroidal Anti-inflammatory Drugs Market, by Country

• 19.1. United States
• 19.2. China
• 19.3. Germany
• 19.4. Canada
• 19.5. Japan
• 19.6. United Kingdom
• 19.7. Brazil
• 19.8. India
• 19.9. Mexico
• 19.10. France
• 19.11. Italy
• 19.12. Russia
• 19.13. Australia
• 19.14. South Korea
• 19.15. Spain

20. Competitive Landscape

• 20.1. Market Share Analysis, 2025
• 20.2. FPNV Positioning Matrix, 2025
• 20.3. Market Concentration Analysis, 2025
  • 20.3.1. Concentration Ratio (CR)
  • 20.3.2. Herfindahl Hirschman Index (HHI)
• 20.4. Recent Developments & Impact Analysis, 2025
• 20.5. Product Portfolio Analysis, 2025
• 20.6. Benchmarking Analysis, 2025

21. Company Profiles

• 21.1. Abbvie, Inc
• 21.2. Algen Healthcare Ltd.
• 21.3. Allegiant Health
• 21.4. Amgen Inc.
• 21.5. Amneal Pharmaceuticals LLC
• 21.6. Arcutis Biotherapeutics, Inc.
• 21.7. Astellas Pharma Inc.
• 21.8. AstraZeneca PLC
• 21.9. BASF SE
• 21.10. Bayer AG
• 21.11. Boehringer Ingelheim GmbH
• 21.12. Bristol-Myers Squibb Company
• 21.13. Clearsynth Labs Limited
• 21.14. Daiichi Sankyo Company, Limited
• 21.15. Dr. Reddy's Laboratories Ltd.
• 21.16. Eisai Co., Ltd.
• 21.17. Eli Lilly and Company
• 21.18. EMS S.A.
• 21.19. Genentech, Inc. by F. Hoffmann-La Roche AG
• 21.20. Gilead Sciences, Inc.
• 21.21. GlaxoSmithKline PLC
• 21.22. Hikma Pharmaceuticals PLC
• 21.23. Incyte Corporation
• 21.24. Johnson & Johnson Services, Inc.
• 21.25. Merck KGaA
• 21.26. Novartis AG
• 21.27. Pfizer Inc.
• 21.28. Pharbest Pharmaceuticals, Inc.
• 21.29. Sandoz International GmbH
• 21.30. Sanofi S.A.
• 21.31. Spectrum Chemical Mfg. Corp.
• 21.32. Sun Pharmaceutical Industries Ltd.
• 21.33. Takeda Pharmaceutical Co. Ltd.
• 21.34. Teikoku Seiyaku Co., Ltd.
• 21.35. Teva Pharmaceutical Industries Ltd.
• 21.36. Verona Pharma plc
• 21.37. Viatris Inc.